Chlorphentermine (trade names Apsedon, Desopimon, Lucofen) is a
serotonergicappetite suppressant of the
amphetamine family. Developed in 1962, it is the 4-chloro derivative of the better known appetite suppressant
phentermine,[2] which is still in current use.
Chlorphentermine acts as a highly selective
serotonin releasing agent (SRA).[3] It is not a
psychostimulant and has little or no
abuse potential, but is classed as a
Schedule III drug in the USA due mainly to its similarity to other appetite suppressants such as
diethylpropion which have been more widely abused. It is no longer used due mainly to safety concerns, as it has a serotonergic effects profile similar to other withdrawn appetite suppressants such as
fenfluramine and
aminorex which were found to cause
pulmonary hypertension and
cardiac fibrosis following prolonged use.[4]
The plasma half-life is about five days.[5] It was withdrawn from the market in the UK in 1974.[5]
^Gylys JA, Hart JJ, Warren MR (September 1962). "Chlorphentermine, a new anorectic agent". The Journal of Pharmacology and Experimental Therapeutics. 137: 365–73.
PMID13903304.
^Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41.
doi:
10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3.
PMID11071707.
S2CID15573624.
Chlorphentermine (trade names Apsedon, Desopimon, Lucofen) is a
serotonergicappetite suppressant of the
amphetamine family. Developed in 1962, it is the 4-chloro derivative of the better known appetite suppressant
phentermine,[2] which is still in current use.
Chlorphentermine acts as a highly selective
serotonin releasing agent (SRA).[3] It is not a
psychostimulant and has little or no
abuse potential, but is classed as a
Schedule III drug in the USA due mainly to its similarity to other appetite suppressants such as
diethylpropion which have been more widely abused. It is no longer used due mainly to safety concerns, as it has a serotonergic effects profile similar to other withdrawn appetite suppressants such as
fenfluramine and
aminorex which were found to cause
pulmonary hypertension and
cardiac fibrosis following prolonged use.[4]
The plasma half-life is about five days.[5] It was withdrawn from the market in the UK in 1974.[5]
^Gylys JA, Hart JJ, Warren MR (September 1962). "Chlorphentermine, a new anorectic agent". The Journal of Pharmacology and Experimental Therapeutics. 137: 365–73.
PMID13903304.
^Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41.
doi:
10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3.
PMID11071707.
S2CID15573624.